LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Disease – First Step Toward Reimbursement
August 07, 2024 06:42 AM Eastern Daylight Time SEATTLE–(BUSINESS WIRE)–LumiThera, Inc., a medical device company commercializing a photobiomodulation (PBM) treatment for ocular damage and disease, today announced a new Category III CPT code effective January 1, 2025. The AMA’s CPT Editorial Panel considered and approved the company’s application for a code to report “Photobiomodulation therapy… Continue reading